
    
      The goal of this study is to evaluate prospectively the economic burden of Multiple Sclerosis
      (MS) in France by calculating direct costs (medical and non-medical) and indirect costs and
      by estimating consequences of MS on utility (QALY) of patients and caregivers in a societal
      perspective.
    
  